Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2. Issue 19 (14th May 2021)

• Record Type: Journal Article
• Authors: Corominas, Hèctor; Castellví, Ivan; Diaz-Torné, César; Matas, Laia; de la Rosa, David; Mangues, Maria Antònia; Moya, Patricia; Pomar, Virginia; Benito, Natividad; Moga, Ester; Sosa, Nerea Hernandez-de; Casademont, Jordi; Domingo, Pere
• Other Names: Tao. Jianli section editor.
• Is Part Of: Medicine. Volume 100:Issue 19(2021)
• Publication Date: 2021-05-14
• Subjects: covid-19 -- critically ill -- sarilumab -- SARS-Cov-2 infection; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000025923
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Blocking IL-6 pathways with sarilumab, a fully human anti–IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used "off-label" sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.